REVOLUTION MEDICINES BEGINS TREATING PATIENTS IN PHASE 3 RASOLUTE 309 TRIAL EVALUATING RASONQUE™ (DARAXONRASIB) PLUS ZOLDONRASIB AS FIRST-LINE TREATMENT FOR METASTATIC RAS G12D PANCREATIC CANCER

Reuters · 1d ago

Please log in to view news